文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

柏林2014/15年麻疹疫情中按年龄估计的疫苗效果与免疫衰减证据

Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity.
PubMed 文献 · Euro Surveill · 2019-01-01

该研究基于德国柏林2014/15年大规模麻疹疫情数据,采用筛查法结合蒙特卡洛模拟估计不同年龄组含麻疹成分疫苗两剂次(MCV2)的疫苗效果(VE)。773例麻疹病例中40例曾接种MCV2,三个最年轻年龄组VE中位数>99%,31-42岁组较低(90.9%,95%CrI:74.1-97.6),提示存在免疫衰减。

要点

  • 三个最年轻年龄组MCV2疫苗效果中位数>99%(95%CrI:98.6-100)。
  • 31-42岁组VE为90.9%(95%CrI:74.1-97.6),低于年轻组。
  • 情景分析提示该年龄组接种比例应足以形成群体免疫,低VE难以完全用自然免疫解释。

核心结论

  • MCV2疫苗效果总体较高,但31-42岁组较低,提示存在免疫衰减。

研究设计与样本

  • 基于柏林2014/15年大规模麻疹疫情的筛查法研究,并先对疫苗接种覆盖率进行系统文献综述。
  • 纳入773例麻疹病例(中位年龄20岁),其中40例曾接种MCV2。
  • 输入变量的不确定性通过蒙特卡洛模拟纳入,并开展情景分析。

主要发现

  • 773例麻疹病例中40例曾接种MCV2,各年龄组平均疫苗覆盖率在32%-88%之间。
  • 三个最年轻年龄组(2-5、6-15、16-23岁)VE中位数>99%(95%CrI:98.6-100)。
  • 31-42岁组VE较低,为90.9%(95%CrI:74.1-97.6)。
  • 情景分析中估计31-42岁组接种MCV2的比例为98.8%(95%CrI:96.5-99.8)。

关键数值与推荐

  • 麻疹消除基于含麻疹成分疫苗两剂次(MCV2)95%覆盖率、高疫苗效果和终生疫苗诱导免疫。
  • 研究按2-5、6-15、16-23、24-30和31-42岁五个年龄组估计VE。
  • 情景分析假设最年轻年龄组自然免疫可忽略,以其VE估计31-42岁组接种比例。

临床怎么用

  • 提示公共卫生监测中应关注成人麻疹疫苗效果随年龄下降的可能。
  • 评估群体免疫时需结合接种覆盖率与年龄别VE,而非仅看覆盖率。
  • 对高龄成人麻疹防控可考虑免疫衰减证据用于加强免疫策略讨论。

局限性

  • 摘要未报告;原文未涉及相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundMeasles elimination is based on 95% coverage with two doses of a measles-containing vaccine (MCV2), high vaccine effectiveness (VE) and life-long vaccine-induced immunity. Longitudinal analysis of antibody titres suggests existence of waning immunity, but the relevance at the population-level is unknown.AimWe sought to assess presence of waning immunity by estimating MCV2 VE in different age groups (2-5, 6-15, 16-23, 24-30 and 31-42 years) in Berlin.MethodsWe conducted a systematic literature review on vaccination coverage and applied the screening-method using data from a large measles outbreak (2014/15) in Berlin. Uncertainty in input variables was incorporated by Monte Carlo simulation. In a scenario analysis, we estimated the proportion vaccinated with MCV2 in those 31-42 years using VE of the youngest age group, where natural immunity was deemed negligible.ResultsOf 773 measles cases (median age: 20 years), 40 had received MCV2. Average vaccine coverage per age group varied (32%-88%). Estimated median VE was > 99% (95% credible interval (CrI): 98.6-100) in the three youngest age groups, but lower (90.9%, 95% CrI: 74.1-97.6) in the oldest age group. In the scenario analysis, the estimated proportion vaccinated was 98.8% (95% CrI: 96.5-99.8).ConclusionVE for MCV2 was generally high, but lower in those aged 31-42 years old. The estimated proportion with MCV2 should have led to sufficient herd immunity in those aged 31-42 years old. Thus, lower VE cannot be fully explained by natural immunity, suggesting presence of waning immunity.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Bitzegeio J, Majowicz S, Matysiak-Klose D, et al. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity. Euro Surveill. 2019. PMID: 31039834. doi:10.2807/1560-7917.ES.2019.24.17.1800529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。